Streetbeat News

Stock Prices

BIO

Bio-Rad Laboratories, Inc. (BIO) has revised its 2023 non-GAAP revenue forecast, now expecting a decline of approximately 3.5% on a currency-neutral basis. This is a significant change from the previous estimate of 0.8% revenue growth.

Portfolio Pulse from Benzinga Newsdesk

October 26, 2023 | 8:47 pm

PGR

A significant bearish stance has been taken on Progressive (NYSE:PGR) as indicated by unusual options activity. The overall sentiment of these big-money traders is 30% bullish and 70% bearish. The whales have been targeting a price range from $130.0 to $160.0 for Progressive over the last 3 months. The current price of PGR is down -1.64% at $153.86. Analysts from various firms have maintained their ratings on Progressive with price targets ranging from $135 to $165.

Portfolio Pulse from Benzinga Insights

October 26, 2023 | 8:46 pm

CRWD

CrowdStrike Holdings (NASDAQ:CRWD) has seen unusual options activity, with a significant number of bearish trades. Whales have been targeting a price range from $75.0 to $190.0 for CrowdStrike over the last 3 months. The company's stock price is currently down by 2.13% at $171.64. Analysts have mixed opinions, with upgrades and downgrades from Jefferies, DA Davidson, JMP Securities, and Argus Research.

Portfolio Pulse from Benzinga Insights

October 26, 2023 | 8:46 pm

MOFG

MidWestOne Financial Gr (NASDAQ:MOFG) reported Q3 earnings of $0.58 per share, beating the analyst consensus estimate of $0.57 by 1.75%. However, this is a 50.43% decrease from the same period last year. The company's quarterly sales of $34.58 million missed the analyst consensus estimate of $37.39 million by 7.53%, marking a 24.40% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

October 26, 2023 | 8:44 pm

CC

Chemours has revised its full-year Adjusted EBITDA forecast to between $1.025 billion and $1.075 billion due to a weaker demand outlook. The company also expects its Adjusted Free Cash Flow guidance to be greater than $225 million.

Portfolio Pulse from Benzinga Newsdesk

October 26, 2023 | 8:43 pm

ELME

Elme Communities (NYSE:ELME) reported Q3 earnings of $0.24 per share, a 4.35% increase YoY. However, the company's quarterly sales of $56.65M missed the analyst consensus estimate of $57.29M by 1.12%. Sales increased by 3.75% compared to the same period last year.

Portfolio Pulse from bharat@benzinga.com

October 26, 2023 | 8:42 pm

CC

Chemours (NYSE:CC) reported Q3 earnings of $0.63 per share, missing the analyst consensus estimate of $0.72 by 12.5%. This is a 49.19% decrease from the same period last year. The company also reported quarterly sales of $1.49 billion, missing the analyst consensus estimate of $1.53 billion by 2.81%. This is a 16.32% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

October 26, 2023 | 8:42 pm

ABCB

Ameris (NASDAQ:ABCB) reported Q3 2023 earnings of $1.16 per share, beating the analyst consensus estimate of $1.12 by 3.57%. However, this is a 12.12% decrease from the same period last year. The company's quarterly sales of $270.93 million missed the analyst consensus estimate of $273.49 million by 0.94%, marking a 2.65% decrease from the same period last year.

Portfolio Pulse from saritha@benzinga.com

October 26, 2023 | 8:39 pm

LODE

Comstock (AMEX:LODE) reported Q3 earnings of $0.11 per share, beating the analyst consensus estimate of $0.02 by 450%. This is a 257.14% increase over losses of $(0.07) per share from the same period last year. However, the company's quarterly sales of $760.72K missed the analyst consensus estimate of $1.16M by 34.42%. This is a 1.81K% increase over sales of $39.85K the same period last year.

Portfolio Pulse from mahesh@benzinga.com

October 26, 2023 | 8:39 pm

RNAZ

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) has announced the commencement of an underwritten public offering of its common stock. The company also expects to grant the underwriters a 45-day option to purchase additional shares equal to 15% of the shares offered in the public offering. The offering is subject to market and other conditions, and there is no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. ThinkEquity is acting as sole book-running manager for the offering.

Portfolio Pulse from Benzinga Newsdesk

October 26, 2023 | 8:36 pm